10.09.2009 17:00:00

Mirion Technologies to Provide Dosimetry System for Swiss Nuclear Power Plant

The Mirion Technologies Health Physics Division announced it has received an order to supply a complete passive dosimetry system based upon Mirion’s patented Direct Ion Storage (DIS) technology to Gösgen Nuclear Power Plant in Switzerland. The plant will be replacing its existing TLD system with DIS-1 and EDIS-1 personal dosimeter badges and DBR-1 dosimeter readers from Mirion’s RADOS product line.

Small, rugged and waterproof, the DIS-1 and EDIS-1 can be read numerous times in a non-destructive manner without losing dose information. This feature allows users to instantly read their accumulated doses whenever necessary. The wide dose and energy range, along with the ability to operate in pulsed fields, makes the DIS dosimeters well-suited for many radiation dosimetry applications.

The DBR-1 dosimeter reader was specifically designed to read DIS-1 and EDIS-1 dosimeters. The reader provides users with an instant dose reading, and stores the dose in a buffer memory for subsequent electronic transmission. This instant reading capability allows users to monitor their dose on a daily basis, and the electronic transmission eliminates the need to send badges to a processing center to obtain an official dose of record.

"We are honored to have been selected to provide a dosimetry system to Gösgen Nuclear Power for addressing both legal and environmental requirements," said Antony Besso, President, of Mirion’s Health Physics Division. "We are committed to providing them with outstanding service levels."

ABOUT MIRION TECHNOLOGIES

Mirion Technologies is a world leader in radiation detection, measuring and monitoring. Mirion has facilities in Europe, Asia, and North America. Mirion Technologies is headquartered in the San Francisco Bay area and is a portfolio company of American Capital (NASDAQ:ACAS).

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Nachrichten zu American Capital Ltdmehr Nachrichten

Keine Nachrichten verfügbar.

Analysen zu American Capital Ltdmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Indizes in diesem Artikel

NASDAQ Comp. 19 480,91 0,40%